NCT02448381
A Phase III Multicenter Randomized Placebo Controlled Study to Determine the Efficacy of Topical SGX301 and Light Irradiation for the Treatment of Cutaneous T-Cell Lymphoma


Adult
The study will to evaluate the efficacy and safety of SGX301 in an ointment at a concentration of 0.25%, applied twice weekly for six weeks, under occlusion for 16-24 hours followed by the administration of visible light up to a dose of 8 joules/cm2 twice weekly for each of three 6-week cycles. The initial cycle compared to a placebo ointment applied for the first treatment cycle. A minimum of 3 and a maximum of 5 lesions will be identified and indexed for treatment and evaluation. In order to ensure that the CAILS assessment is based on the same number of lesions for each patient, the investigator (prior to randomization) will select 3 of the lesions in each patient for primary evaluation in the first two cycles of treatment.

 See full details

NCT02751151
Photodynamic therapy for prevention of non-melanoma


Adult
The study will draw patients from the Transplant Dermatology specialty clinic, where the investigators see organ transplant recipients (OTR) for regular screening and serve as a regional referral center for this population. Enrollment will be limited to 20 patients. Inclusion criteria are organ transplant recipients status, active immunosuppression for at least 5 years, and history of at least one NMSC.

 See full details

16-2427
Pilot Study of Neoantigen Profiling in Patients with Melanoma Treated with PD-1 Blockade


Adult
This research study is designed to better understand the molecular determinants of response to immunotherapies including pembrolizumab and nivolumab. We hope to learn the relevance of tumor neoantigens in the recognition of cancer cells by the immune system. The ultimate goal is to rank and filter these neoantigens and correlate with response to immunotherapies.

 See full details

NCT02811783
Elorac, Inc. / A Double Blind, Randomized, Vehicle Controlled, Crossover Study to Evaluate the Safety and Efficacy of Topical Naloxone Hydrochloride Lotion, 0.5%, for the Relief of Pruritus in Patients with the Mycosis Fungoides (MF) or Sézary Syndrome (SS) Forms of Cutaneous T-Cell Lymphoma (CTCL)


Adult
This multi-center, double-blind, vehicle-controlled, randomized crossover design study will evaluate the safety and efficacy of topically applied naloxone lotion, 0.5%, for the treatment of pruritus in patients with the mycosis fungoides (MF) or Sézary syndrome (SS) Forms of Cutaneous T-cell Lymphoma (CTCL). This study will also determine if there is systemic absorption of the drug in a subset of subjects and if so, describe the range and mean plasma levels reached after two weeks of three time daily (TID) dosing.

 See full details

NCT03635983
BMS CA045-001: A Phase 3, Randomized, Open-label Study of NKTR-214 Combined with Nivolumab versus Nivolumab in Participants with Previously Untreated Unresectable or Metastatic Melanoma


Adult
The purpose of the study is to test the effectiveness (how well the drug works), safety, and tolerability of the investigational drug called NKTR-214 , when combined with nivolumab versus nivolumab given alone in participants with previously untreated melanoma skin cancer that is either unable to be surgically removed or has spread. NKTR-214 and nivolumab in this informed consent may also be referred to as study medication(s) or treatment.

 See full details

NCT03553836
KEYNOTE 716: Adjuvant Therapy with Pembrolizumab versus Placebo in Resected High risk Stage II Melanoma: A Randomized, Double-blind Phase 3 Study


Adult
The purpose of this study is to: test the safety of the research study drug, Pembrolizumab (MK-3475), also known as KEYTRUDA® and see how well the study drug, pembrolizumab, works compared to placebo in keeping cancer from coming back or spreading.

 See full details

NCT03138889
Propel: A Phase 1B, open-label, multicenter study to investigate the safety and preliminary efficacy of NKTR-214 in combination with Anti-PD-1 (Pembrolizumab) or Anti-PD-L1 (Atezolizumab) in patients with locally advanced or metastatic solid tumors


Adult
The purpose of this study is to test the safety, tolerability, and effectiveness of NKTR-214 given in combination with KEYTRUDA®

 See full details

NCT03445533
A Study of IMO-2125 in Combination With Ipilimumab Versus Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma (ILLUMINATE-301)


Adult
Refractory melanoma is a type of cancer mainly found on the skin, which may not be responding to available treatments. Researchers have developed a drug called IMO-2125 (sometimes referred to as "study drug"), which may be used to treat refractory melanoma. This is an investigational study, which means the study drug is experimental and is not approved by the U.S. Food and Drug Administration (FDA). The study is being done to compare the effectiveness of the study drug given in combination with ipilimumab (Yervoy®) compared to ipilimumab given alone.

 See full details

NCT03820986
A Phase 3 Randomized, Placebo-controlled Trial to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) and Lenvatinib (E7080/MK-7902) Versus Pembrolizumab Alone as First-line Intervention in Participants with Advanced Melanoma (LEAP-003)


Adult
The purpose of this study is to:
  • See how well the combination of study drugs (lenvatinib and pembrolizumab) work together
  • Test the safety and how well your body handles the combination of the study drugs
  • Find out how lenvatinib is absorbed and broken down in your body when given with pembrolizumab
  • Test the combination of the study drugs and see if they help patients live longer


 See full details

NCT03776136
A Multicenter, Open-label, Phase 2 Trial to Assess the Efficacy and Safety of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Melanoma Previously Exposed to an Anti-PD-1/L1 Agent (LEAP-004)


Adult
The purpose of this study is to:
  • Test the safety of the study drugs, lenvatinib and pembrolizumab, to see how well the combination of study drugs work together, see how your body handles the combination of the study drugs.
  • Find out how lenvatinib is absorbed and broken down in your body when given with pembrolizumab
  • Test the combination of the study drugs and see if they help patients live longer


 See full details

NCT03833167
A Phase 3, Randomized, Doubleblind, Placebo-controlled Study to Evaluate Pembrolizumab Versus Placebo as Adjuvant Therapy Following Surgery and Radiation in Participants with High-risk Locally Advanced Cutaneous Squamous Cell Carcinoma (LA cSCC) (KEYNOTE-630)


Adult
The purpose of this study is to test the safety of the study drug, pembrolizumab, and whether it keeps your type of cancer from coming back or spreading compared to placebo. The purpose of this study is also to see if giving pembrolizumab after surgery and radiation helps patients with your type of cancer live longer.

 See full details

NCT03599713
A Phase 2 Study of INCMGA-0012 in Participants with Metastatic Merkel Cell Carcinoma (PODIUM)


Adult
The purpose of this study is to test the safety and effectiveness of the study drug INCMGA00012 in participants with Metastatic Merkel Cell Carcinoma.

 See full details

NCT03787602
A Phase 2, Open-Label, Single-Arm Study of KRT-232 in Patients With p53 Wild-Type (p53WT) Merkel Cell Carcinoma (MCC) Who Have Failed Anti-PD-1 or Anti-PD-L1 Immunotherapy


Adult
For participants diagnosed with Merkel cell carcinoma (MCC) and prior treatment with anti-PD-1 or anti-PD-L1 was not or is no longer effective. This is the first study of KRT-232 in patients with MCC after prior treatment with anti-PD-1 or anti-PD-L1 and it will evaluate how well tolerated KRT-232 is when given to participants with MCC, and whether KRT-232 can improve MCC outcomes. KRT-232 (formerly called AMG 232) is an investigational drug in a tablet form that is taken by mouth. KRT-232 has been shown in the laboratory to inhibit the growth of some tumor cells.

 See full details

NCT02890368
A Phase 1 Dose Escalation Trial of Intratumoral Injections of TTI-621 in Subjects with Relapsed and Refractory Percutaneously Accessible Solid Tumors and Mycosis Fungoides


Adult
TTI-621 is a type of protein called a fusion protein which is similar to an antibody. It is designed to target and block a protein called CD47. CD47 is present on cancer cells and is used by cancer cells to hide from your body’s immune system. Blocking CD47 with TTI-621 may help your body’s immune system find and destroy the cancer cells. This study is also being done to understand how the body absorbs and processes different doses of TTI-621 by measuring the levels of the study drug in the blood at different times. This is called pharmacokinetics (PK) testing. This study is also being conducted to understand how TTI-621 affects the body, such as its effect on the immune system; and to understand the side effects and possible benefit when TTI-621 is given alone and also together with different FDA approved anti-cancer treatments.

 See full details

NCT0383610
CemiplimAb Survivorship Epidemiology (CASE)


Adult
This is a prospective survivorship study of adult patients with Cutaneous Squamous cell Carcinoma (CSCC) who receive treatment with commercially available cemiplimab. The objectives of the study are to identify potential determinants of disease progression, Quality of Life (QOL), and other health-related outcomes. The study also looks to assess patient experience, QOL and functional status, in a real-world setting for patients with CSCC. The information collected from the study will be used to better understand the long-term effectiveness and safety of cemiplimab-rwlc in patients. Cemiplimab-rwlc has been approved by the U.S. FDA for treatment of advanced cutaneous squamous cell carcinoma.

 See full details

NCT02465060
NCI MATCH Molecular Analysis for Therapy Choice


Adult
This phase II MATCH trial studies how well treatment that is directed by genetic testing works in patients with solid tumors or lymphomas that have progressed following at least one line of standard treatment or for which no agreed upon treatment approach exists. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic abnormalities (such as mutations, amplifications, or translocations) may benefit more from treatment which targets their tumor's particular genetic abnormality. Identifying these genetic abnormalities first may help doctors plan better treatment for patients with solid tumors, lymphomas, or multiple myeloma.

 See full details

NCT02693535
The Targeted Agent and Profiling Utilization Registry (TAPUR) Study


Adult
The Targeted Agent and Profiling Utilization Registry (TAPUR) Study is a non-randomized clinical trial that aims to describe the performance (both safety and efficacy) of commercially available, targeted anticancer drugs prescribed for treatment of patients with advanced cancer that has a potentially actionable genomic variant. The study provides approved targeted therapies that are contributed to the program by collaborating pharmaceutical companies, catalogues the choice of genomic profiling test by clinical oncologists and aims to learn about the utility of registry data to develop hypotheses for additional clinical trials. 

 See full details